These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

833 related items for PubMed ID: 27239721

  • 1. Inhibitors of histone deacetylase as antitumor agents: A critical review.
    Manal M, Chandrasekar MJ, Gomathi Priya J, Nanjan MJ.
    Bioorg Chem; 2016 Aug; 67():18-42. PubMed ID: 27239721
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P, Sun F, Hou X, Wang F, Yi F, Xu W, Fang H.
    Bioorg Med Chem; 2012 Jun 15; 20(12):3865-72. PubMed ID: 22579621
    [Abstract] [Full Text] [Related]

  • 4. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
    Liu R, Wang J, Tang W, Fang H.
    Bioorg Med Chem; 2016 Apr 01; 24(7):1446-54. PubMed ID: 26907204
    [Abstract] [Full Text] [Related]

  • 5. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
    Negmeldin AT, Pflum MKH.
    Bioorg Med Chem Lett; 2017 Aug 01; 27(15):3254-3258. PubMed ID: 28648461
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
    Chen Y, Wang X, Xiang W, He L, Tang M, Wang F, Wang T, Yang Z, Yi Y, Wang H, Niu T, Zheng L, Lei L, Li X, Song H, Chen L.
    J Med Chem; 2016 Jun 09; 59(11):5488-504. PubMed ID: 27186676
    [Abstract] [Full Text] [Related]

  • 8. Quinolone-based HDAC inhibitors.
    Balasubramanian G, Kilambi N, Rathinasamy S, Rajendran P, Narayanan S, Rajagopal S.
    J Enzyme Inhib Med Chem; 2014 Aug 09; 29(4):555-62. PubMed ID: 25019596
    [Abstract] [Full Text] [Related]

  • 9. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT, Knoff JR, Pflum MKH.
    Eur J Med Chem; 2018 Jan 01; 143():1790-1806. PubMed ID: 29150330
    [Abstract] [Full Text] [Related]

  • 10. Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
    Cho M, Choi E, Kim JH, Kim H, Kim HM, Lee JI, Hwang KC, Kim HJ, Han G.
    ChemMedChem; 2014 Mar 01; 9(3):649-56. PubMed ID: 24376239
    [Abstract] [Full Text] [Related]

  • 11. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
    Pojani E, Barlocco D.
    Curr Med Chem; 2021 Mar 01; 28(7):1290-1303. PubMed ID: 32013816
    [Abstract] [Full Text] [Related]

  • 12. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents.
    Tung TT, Oanh DT, Dung PT, Hue VT, Park SH, Han BW, Kim Y, Hong JT, Han SB, Nam NH.
    Med Chem; 2013 Dec 01; 9(8):1051-7. PubMed ID: 23521008
    [Abstract] [Full Text] [Related]

  • 13. HDAC Inhibitors as Novel Anti-Cancer Therapeutics.
    De Souza C, Chatterji BP.
    Recent Pat Anticancer Drug Discov; 2015 Dec 01; 10(2):145-62. PubMed ID: 25782916
    [Abstract] [Full Text] [Related]

  • 14. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT, Anh DT, Hai PT, Huong LT, Park EJ, Choi JE, Kang JS, Dung PTP, Han SB, Nam NH.
    Chem Biodivers; 2018 Jun 01; 15(6):e1800027. PubMed ID: 29667768
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
    Zhu Y, Chen X, Wu Z, Zheng Y, Chen Y, Tang W, Lu T.
    Arch Pharm Res; 2012 Oct 01; 35(10):1723-32. PubMed ID: 23139122
    [Abstract] [Full Text] [Related]

  • 16. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V, Cappelletti G, Casagrande M, Perrino E, Renzi L, Del Soldato P, Sparatore A.
    Bioorg Med Chem; 2010 Jun 15; 18(12):4187-94. PubMed ID: 20576572
    [Abstract] [Full Text] [Related]

  • 17. Novel inhibitors of human histone deacetylases: design, synthesis and bioactivity of 3-alkenoylcoumarines.
    Seidel C, Schnekenburger M, Zwergel C, Gaascht F, Mai A, Dicato M, Kirsch G, Valente S, Diederich M.
    Bioorg Med Chem Lett; 2014 Aug 15; 24(16):3797-801. PubMed ID: 25042254
    [Abstract] [Full Text] [Related]

  • 18. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
    Ojha R, Huang HL, HuangFu WC, Wu YW, Nepali K, Lai MJ, Su CJ, Sung TY, Chen YL, Pan SL, Liou JP.
    Eur J Med Chem; 2018 Apr 25; 150():667-677. PubMed ID: 29567459
    [Abstract] [Full Text] [Related]

  • 19. Improved antiproliferative activity of 1,3,4-thiadiazole-containing histone deacetylase (HDAC) inhibitors by introduction of the heteroaromatic surface recognition motif.
    Guan P, Wang L, Hou X, Wan Y, Xu W, Tang W, Fang H.
    Bioorg Med Chem; 2014 Nov 01; 22(21):5766-75. PubMed ID: 25311567
    [Abstract] [Full Text] [Related]

  • 20. 5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.
    Huong TT, Dung do TM, Oanh DT, Lan TT, Dung PT, Loi VD, Kim KR, Han BW, Yun J, Kang JS, Kim Y, Han SB, Nam NH.
    Med Chem; 2015 Nov 01; 11(3):296-304. PubMed ID: 25256241
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.